Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study.

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Abstract Text:

Jeffrey A Claridge,Norma M Edwards,Joseph Swanson,Timothy C Fabian,Jordan A Weinberg,Christopher Wood,Martin A Croce,

BACKGROUND: Ventilator-associated pneumonia (VAP) is a frequent complication during recovery of severely traumatized patients. The primary objective of this study was to determine if prophylactic administration of aerosolized ceftazidime reduced the incidence of VAP in high-risk injured patients without altering the incidence of other infectious complications. PATIENTS AND METHODS: This was a single-institution double-blind, randomized trial that compared a seven-day course of aerosolized ceftazidime with placebo. Intubated high-risk patients admitted to the trauma intensive care unit at a large regional trauma center between February 2003 and September 2005 were eligible for enrollment. The main outcome evaluated was the incidence of VAP at two weeks and 30 days. The incidences of multi-drug-resistant infections and other infectious complications were secondary outcomes. Results: A total of 105 patients were randomized, resulting in 52 patients in the placebo arm and 53 patients in the ceftazidime arm. There was no statistical difference between the groups with regard to demographic data, injury severity, calculated risk of VAP, or the number of doses received. In the intention-to-treat analysis, the incidence of VAP at two weeks was 24/52 (46%) in the placebo group and 21/53 (40%) in the ceftazidime group. The number of patients with VAP at 30 days was 26/52 (50%) in the placebo group and 26/53 (49%) in the ceftazidime group. There was no statistical difference in the development of multi-drug-resistant VAP or other infectious complications in the two groups. CONCLUSION: The use of aerosolized ceftazidime did not reduce the rate of VAP in high-risk patients admitted after traumatic injury, but neither did it increase the incidence of other infectious complications. Routine use of prophylactic aerosolized ceftazidime to prevent VAP in trauma patients cannot be recommended.

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Publishing Authors By Initials

JA Claridge,NM Edwards,J Swanson,TC Fabian,JA Weinberg,C Wood,MA Croce,

For similar disorders of environmental origin: wounds and injuries research abstracts see: disorders of environmental origin: wounds and injuries research

PUBMED ID PMID:

MEDLINE DATE:

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Surgical infections

VOLUME: 8

Page Numbers: 83-90

Journal Abbreviation:

ISSN: 1096-2964

DAY: 3

MONTH: Feb

YEAR: 2007

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9815642

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Keywords Mesh Terms:

KEYWORDS: Wounds and Injuries

MESH TERMS: complications

Chemical & Substance for Abstract: Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Information

Substance Name: Ceftazidime

Registry Number: 78439-06-2

Grant and Affiliation Information for Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study.

AFFILIATION: Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA. jclaridge@metrohealth.org

Country: United States

AGENCY: United States NICHD

GRANT: K12 HD 04091

ACRONYM: HD

MEDLINETA: Surg Infect (Larchmt)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study Related Publications

• A multicentre double-blind group comparative trial of two dose levels of nedocromil sodium and placebo in the management of perennial extrinsic asthma.
• A specific binding site for neoxanthin in the monomeric antenna proteins CP26 and CP29 of Photosystem II.
• ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias.
• Acute colonic obstruction: endoscopic stenting and laparoscopic resection.
• Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study.
• Analyses of isokinetic and closed chain movements for hamstring reciprocal coactivation.
• Cellular localization of the bcl-2 protein and response to glucocorticoid stress.
• Chromosomal proteins of mouse teratocarcinoma cells.
• Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: results of a randomized trial.
• Expression profiling of microRNA using oligo DNA arrays.
• Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo.
• Investigation of MicroRNA Alterations in Leukemias and Lymphomas.
• Laparoscopic repair of inguinal hernias using an intraperitoneal onlay mesh technique and a Parietex composite mesh fixed with fibrin glue (Tissucol). Personal technique and preliminary results.
• MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
• MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.
• MicroRNA signatures in human ovarian cancer.
• MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
• MicroRNAs in carcinogenesis.
• Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock.
• Oncogenes and cancer.
• Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing.
• Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
• Targeted deletion of Wwox reveals a tumor suppressor function.
• Use of fibrin glue (Tissucol) as a hemostatic in laparoscopic conservative treatment of spleen trauma.
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]